AZTR
Azitra, Inc.
Price Chart
Latest Quote
$0.19
| Previous Close | $0.18 |
| Open | $0.32 |
| Day High | $0.32 |
| Day Low | $0.18 |
| Volume | 375,577,595 |
Stock Information
| Shares Outstanding | 16.19M |
| Total Debt | $343K |
| Cash Equivalents | $10.05M |
| Net Income | $-11.81M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.10M |
| EPS (TTM) | $-0.88 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-6.73M |
| Income | $-11.81M |
| Book/sh | $0.65 |
| Cash/sh | $0.62 |
| Employees | 13 |
Financial Ratios
| Quick Ratio | 6.58 |
| Current Ratio | 6.94 |
| Debt/Eq | 3.28 |
Returns & Margins
| ROA | -81.79% |
| ROE | -158.71% |
Ownership
| Insider Ownership | 3.38% |
| Institutional Ownership | 3.33% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.37 |
| P/B | 0.30 |
Analyst Data
| Recommendation | none |
| Target Price | $0.78 |
Technical Indicators
| SMA20 | $0.21 |
| SMA50 | $0.22 |
| SMA200 | $0.36 |
| RSI | 45.75 |
| ATR | 0.0281 |
| Shares Float | 16.18M |
| Short Float | 0.58% |
| Short Ratio | 0.11 |
| Volatility | -1.28 |
| Rel Volume | 19.52 |
Performance History
| Week | -19.66% |
| Month | +0.63% |
| Quarter | +39.56% |
| 6 Months | -36.27% |
| YTD | -31.47% |
| Year | -89.38% |
| 10 Years | -99.98% |
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $0.20 | 377,935,029 |
| 2026-06-16 | $0.18 | 850,900 |
| 2026-06-15 | $0.20 | 719,000 |
| 2026-06-12 | $0.21 | 212,900 |
| 2026-06-11 | $0.22 | 192,600 |
| 2026-06-10 | $0.24 | 505,700 |
| 2026-06-09 | $0.21 | 365,200 |
| 2026-06-08 | $0.20 | 357,600 |
| 2026-06-05 | $0.21 | 127,800 |
| 2026-06-04 | $0.22 | 204,900 |
| 2026-06-03 | $0.22 | 269,900 |
| 2026-06-02 | $0.22 | 279,900 |
| 2026-06-01 | $0.22 | 419,200 |
| 2026-05-29 | $0.23 | 1,370,500 |
| 2026-05-28 | $0.20 | 408,600 |
| 2026-05-27 | $0.21 | 539,900 |
| 2026-05-26 | $0.21 | 322,100 |
| 2026-05-22 | $0.20 | 542,900 |
| 2026-05-21 | $0.21 | 693,700 |
| 2026-05-20 | $0.20 | 752,000 |
| 2026-05-19 | $0.19 | 404,000 |
| 2026-05-18 | $0.19 | 626,800 |
About Azitra, Inc.
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.
đ° Latest News
Wall Street Set to Open Higher Monday as Investors Look Ahead to a Week of Earnings Reports
MT Newswires âĸ 2025-10-20T13:27:01ZWhy Is Azitra (AZTR) Stock Soaring Today
GuruFocus.com âĸ 2025-08-27T20:44:20ZSector Update: Health Care Stocks Mixed Late Afternoon
MT Newswires âĸ 2025-08-27T19:41:55ZSector Update: Health Care Stocks Advance Wednesday Afternoon
MT Newswires âĸ 2025-08-27T17:59:06ZIncome Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $7,500 | $686,000 | $284,000 |
| Operating Revenue | $0 | $7,500 | $686,000 | $284,000 |
| Expenses | ||||
| Interest Expense | $7,587 | $12,160 | $167,726 | $251,891 |
| Total Expenses | $10,966,665 | $10,992,640 | $8,136,546 | $9,737,604 |
| Other Income Expense | $-43,008 | $1,916,286 | $-3,649,778 | $-979,689 |
| Other Non Operating Income Expenses | $-43,389 | $-2,117,786 | $-3,684,708 | $-979,689 |
| Net Non Operating Interest Income Expense | $62,622 | $110,393 | $-166,149 | $-247,073 |
| Interest Expense Non Operating | $7,587 | $12,160 | $167,726 | $251,891 |
| Operating Expense | $10,966,665 | $10,992,640 | $8,136,546 | $9,737,604 |
| General And Administrative Expense | $6,130,657 | $6,269,262 | $4,493,332 | $3,639,666 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-10,955,370 | $-8,967,492 | $-11,283,781 | $-10,680,366 |
| Net Interest Income | $62,622 | $110,393 | $-166,149 | $-247,073 |
| Interest Income | $70,209 | $122,553 | $1,577 | $4,818 |
| Normalized Income | $-10,955,671 | $-12,154,409 | $-11,311,376 | $-10,680,366 |
| Net Income From Continuing And Discontinued Operation | $-10,955,370 | $-8,967,492 | $-11,283,781 | $-10,680,366 |
| Total Operating Income As Reported | $-10,966,665 | $-10,985,140 | $-7,450,546 | $-9,453,604 |
| Net Income Common Stockholders | $-10,955,370 | $-8,967,492 | $-12,639,128 | $-13,449,350 |
| Net Income | $-10,955,370 | $-8,967,492 | $-11,283,781 | $-10,680,366 |
| Net Income Including Noncontrolling Interests | $-10,955,370 | $-8,967,492 | $-11,283,781 | $-10,680,366 |
| Net Income Continuous Operations | $-10,955,370 | $-8,967,492 | $-11,283,781 | $-10,680,366 |
| Pretax Income | $-10,947,051 | $-8,958,461 | $-11,266,473 | $-10,680,366 |
| Interest Income Non Operating | $70,209 | $122,553 | $1,577 | $4,818 |
| Operating Income | $-10,966,665 | $-10,985,140 | $-7,450,546 | $-9,453,604 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-2.25 | $-15.70 | $-366.17 | $-222.33 |
| Basic EPS | $-2.25 | $-15.70 | $-366.17 | $-222.33 |
| Other | ||||
| Tax Effect Of Unusual Items | $80 | $847,155 | $7,335 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-10,486,701 | $-12,532,137 | $-10,708,128 | $-10,022,498 |
| Total Unusual Items | $381 | $4,034,072 | $34,930 | $0 |
| Total Unusual Items Excluding Goodwill | $381 | $4,034,072 | $34,930 | $0 |
| Reconciled Depreciation | $453,144 | $448,236 | $425,549 | $405,977 |
| EBITDA (Bullshit earnings) | $-10,486,320 | $-8,498,065 | $-10,673,198 | $-10,022,498 |
| EBIT | $-10,939,464 | $-8,946,301 | $-11,098,747 | $-10,428,475 |
| Diluted Average Shares | $4,873,552 | $571,162 | $34,514 | $60,493 |
| Basic Average Shares | $4,873,552 | $571,162 | $34,514 | $60,493 |
| Diluted NI Availto Com Stockholders | $-10,955,370 | $-8,967,492 | $-12,639,128 | $-13,449,350 |
| Tax Provision | $8,319 | $9,031 | $17,308 | $0 |
| Gain On Sale Of Security | $381 | $4,034,072 | $34,930 | - |
| Research And Development | $4,836,008 | $4,723,378 | $3,643,214 | $6,097,938 |
| Selling General And Administration | $6,130,657 | $6,269,262 | $4,493,332 | $3,639,666 |
| Other Gand A | $6,130,657 | $6,269,262 | $4,493,332 | $3,639,666 |
| Preferred Stock Dividends | - | - | $1,355,347 | $2,768,984 |
| Other Special Charges | - | - | - | - |
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $3,484,557 | $5,451,878 | $2,702,265 | $-36,479,877 |
| Total Assets | $5,025,386 | $7,358,802 | $5,115,486 | $7,167,443 |
| Total Non Current Assets | $2,006,059 | $2,130,512 | $2,579,907 | $3,031,560 |
| Other Non Current Assets | $47,402 | $46,941 | $47,760 | $47,507 |
| Non Current Deferred Assets | $679,908 | $631,279 | $742,229 | $800,831 |
| Goodwill And Other Intangible Assets | $316,673 | $246,420 | $210,881 | $219,567 |
| Other Intangible Assets | $316,673 | $246,420 | $210,881 | $219,567 |
| Current Assets | $3,019,327 | $5,228,290 | $2,535,579 | $4,135,883 |
| Current Deferred Assets | $0 | $4,106 | $67,859 | $216,886 |
| Prepaid Assets | $809,949 | $567,569 | $448,257 | $160,133 |
| Receivables | $141,295 | $101,896 | $223,474 | $266,208 |
| Taxes Receivable | $140,383 | $101,663 | $125,219 | $83,388 |
| Accounts Receivable | $912 | $233 | $98,255 | $182,820 |
| Cash Cash Equivalents And Short Term Investments | $2,068,083 | $4,554,719 | $1,795,989 | $3,492,656 |
| Cash And Cash Equivalents | $2,068,083 | $4,554,719 | $1,795,989 | $3,492,656 |
| Debt | ||||
| Total Debt | $422,077 | $555,509 | $885,947 | $7,728,280 |
| Long Term Debt And Capital Lease Obligation | $156,190 | $284,266 | $563,692 | $7,440,896 |
| Current Debt And Capital Lease Obligation | $265,887 | $271,243 | $322,255 | $287,384 |
| Net Debt | - | - | - | $3,107,344 |
| Long Term Debt | - | - | - | $6,600,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,224,156 | $1,660,504 | $2,202,340 | $43,427,753 |
| Total Non Current Liabilities Net Minority Interest | $156,190 | $284,647 | $599,145 | $41,205,721 |
| Derivative Product Liabilities | $0 | $381 | $35,453 | $70,283 |
| Current Liabilities | $1,067,966 | $1,375,857 | $1,603,195 | $2,222,032 |
| Other Current Liabilities | $198,983 | - | - | - |
| Payables And Accrued Expenses | $565,216 | $1,071,645 | $1,249,866 | $1,751,566 |
| Payables | $405,612 | $501,827 | $897,272 | $784,687 |
| Total Tax Payable | $6,256 | $11,572 | $0 | $0 |
| Income Tax Payable | $6,256 | $11,572 | $0 | $0 |
| Accounts Payable | $399,356 | $490,255 | $897,272 | $784,687 |
| Current Deferred Liabilities | - | - | $0 | $156,000 |
| Interest Payable | - | - | $0 | $223,792 |
| Equity | ||||
| Common Stock Equity | $3,801,230 | $5,698,298 | $2,913,146 | $-36,260,310 |
| Total Equity Gross Minority Interest | $3,801,230 | $5,698,298 | $2,913,146 | $-36,260,310 |
| Stockholders Equity | $3,801,230 | $5,698,298 | $2,913,146 | $-36,260,310 |
| Retained Earnings | $-68,521,196 | $-57,565,825 | $-48,597,163 | $-37,314,552 |
| Preferred Securities Outside Stock Equity | - | - | $0 | $33,694,542 |
| Other | ||||
| Ordinary Shares Number | $10,740,697 | $1,145,053 | $60,548 | $60,493 |
| Share Issued | $10,740,697 | $1,145,053 | $60,548 | $60,493 |
| Tangible Book Value | $3,484,557 | $5,451,878 | $2,702,265 | $-36,479,877 |
| Invested Capital | $3,801,230 | $5,698,298 | $2,913,146 | $-29,660,310 |
| Working Capital | $1,951,361 | $3,852,433 | $932,384 | $1,913,851 |
| Capital Lease Obligations | $422,077 | $555,509 | $885,947 | $1,128,280 |
| Total Capitalization | $3,801,230 | $5,698,298 | $2,913,146 | $-29,660,310 |
| Additional Paid In Capital | $72,321,352 | $63,264,009 | $51,510,269 | $1,054,138 |
| Capital Stock | $1,074 | $114 | $40 | $104 |
| Common Stock | $1,074 | $114 | $40 | $104 |
| Preferred Stock | $0 | $0 | $0 | - |
| Long Term Capital Lease Obligation | $156,190 | $284,266 | $563,692 | $840,896 |
| Current Capital Lease Obligation | $265,887 | $271,243 | $322,255 | $287,384 |
| Pensionand Other Post Retirement Benefit Plans Current | $37,880 | $32,969 | $31,074 | $27,082 |
| Current Accrued Expenses | $159,604 | $569,818 | $352,594 | $966,879 |
| Net PPE | $962,076 | $1,205,872 | $1,579,037 | $1,963,655 |
| Accumulated Depreciation | $-633,045 | $-515,003 | $-401,987 | $-286,549 |
| Gross PPE | $1,595,121 | $1,720,875 | $1,981,024 | $2,250,204 |
| Leases | $28,855 | $28,855 | $28,855 | $28,855 |
| Other Properties | $1,500,345 | $1,621,947 | $1,882,096 | $2,151,276 |
| Machinery Furniture Equipment | $50,989 | $55,141 | $55,141 | $55,141 |
| Buildings And Improvements | $14,932 | $14,932 | $14,932 | $14,932 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Shares Number | - | - | $0 | - |
| Current Deferred Revenue | - | - | $0 | $156,000 |
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-11,410,187 | $-10,562,986 | $-7,680,634 | $-8,690,480 |
| Operating Activities | ||||
| Operating Cash Flow | $-11,224,125 | $-10,183,740 | $-7,362,375 | $-8,349,469 |
| Cash Flow From Continuing Operating Activities | $-11,224,125 | $-10,183,739 | $-7,362,375 | $-8,349,469 |
| Operating Gains Losses | $1,688 | $-4,043,411 | $-49,698 | $7,102 |
| Investing Activities | ||||
| Capital Expenditure | $-186,062 | $-379,246 | $-318,259 | $-341,011 |
| Investing Cash Flow | $-182,909 | $-379,246 | $-318,259 | $-336,761 |
| Cash Flow From Continuing Investing Activities | $-182,909 | $-379,246 | $-318,259 | $-336,761 |
| Capital Expenditure Reported | $-161,849 | $-370,677 | $-291,715 | $-307,910 |
| Net Other Investing Changes | - | - | - | $-180,802 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $9,033,322 | $13,354,691 | $5,991,359 | $0 |
| Financing Cash Flow | $8,920,398 | $13,321,716 | $5,983,967 | $4,134,624 |
| Cash Flow From Continuing Financing Activities | $8,920,398 | $13,321,716 | $5,983,967 | $4,134,624 |
| Net Other Financing Charges | $-96,863 | $-37,477 | - | $-216,886 |
| Net Common Stock Issuance | $9,033,322 | $13,354,691 | $5,991,359 | $0 |
| Common Stock Issuance | $9,033,322 | $13,354,691 | $5,991,359 | $0 |
| Other | ||||
| Repayment Of Debt | $-16,061 | $-14,598 | $-7,392 | $0 |
| End Cash Position | $2,068,083 | $4,554,719 | $1,795,989 | $3,492,656 |
| Beginning Cash Position | $4,554,719 | $1,795,989 | $3,492,656 | $8,044,262 |
| Changes In Cash | $-2,486,636 | $2,758,730 | $-1,696,667 | $-4,551,606 |
| Proceeds From Stock Option Exercised | $0 | $19,100 | $0 | $1,510 |
| Net Issuance Payments Of Debt | $-16,061 | $-14,598 | $-7,392 | $4,350,000 |
| Net Long Term Debt Issuance | $-16,061 | $-14,598 | $-7,392 | $4,350,000 |
| Long Term Debt Payments | $-16,061 | $-14,598 | $-7,392 | $0 |
| Net PPE Purchase And Sale | $-21,060 | $-8,569 | $-26,544 | $-28,851 |
| Sale Of PPE | $3,153 | $0 | $0 | $4,250 |
| Purchase Of PPE | $-24,213 | $-8,569 | $-26,544 | $-33,101 |
| Change In Working Capital | $-797,227 | $-441,718 | $-753,429 | $310,761 |
| Change In Other Working Capital | $-5,316 | $18,408 | $-156,000 | $141,000 |
| Change In Other Current Liabilities | $-304,913 | $-315,840 | $-283,102 | $-268,509 |
| Change In Other Current Assets | $-461 | $819 | $-253 | $694 |
| Change In Payables And Accrued Expense | $-500,318 | $-140,535 | $-68,684 | $420,752 |
| Change In Prepaid Assets | $53,180 | $-119,312 | $-288,124 | $-49,844 |
| Change In Receivables | $-39,399 | $114,742 | $42,734 | $66,668 |
| Changes In Account Receivables | $-679 | $98,022 | $84,565 | $-21,953 |
| Other Non Cash Items | $10,896 | $2,132,799 | $3,796,119 | $1,422,592 |
| Stock Based Compensation | $62,744 | $245,053 | $151,505 | $184,465 |
| Asset Impairment Charge | $0 | $442,793 | $351,360 | $0 |
| Depreciation Amortization Depletion | $453,144 | $448,236 | $425,549 | $405,977 |
| Depreciation And Amortization | $453,144 | $448,236 | $425,549 | $405,977 |
| Amortization Cash Flow | $13,712 | $11,163 | $7,643 | - |
| Amortization Of Intangibles | $13,712 | $11,163 | $7,643 | - |
| Depreciation | $439,432 | $437,073 | $417,906 | $405,977 |
| Gain Loss On Investment Securities | $-381 | $-4,034,072 | $-34,830 | $-821 |
| Net Foreign Currency Exchange Gain Loss | $0 | $-14,198 | $0 | - |
| Gain Loss On Sale Of PPE | $2,069 | $4,859 | $41,417 | $7,923 |
| Net Income From Continuing Operations | $-10,955,370 | $-8,967,492 | $-11,283,781 | $-10,680,366 |
| Change In Payable | - | $-140,535 | $-68,684 | $420,752 |
| Change In Account Payable | - | $-140,535 | $-68,684 | $420,752 |
| Issuance Of Debt | - | - | $0 | $4,350,000 |
| Long Term Debt Issuance | - | - | $0 | $4,350,000 |
| Net Intangibles Purchase And Sale | - | - | - | $-127,108 |
| Purchase Of Intangibles | - | - | - | $-127,108 |
| Change In Tax Payable | - | - | - | $0 |
| Change In Income Tax Payable | - | - | - | $0 |